Immuneering Corp
@Immuneering
Following the recent announcement highlighting positive overall survival data from our ongoing Phase 2a trial in #PancreaticCancer, we were proud to participate in the Closing Bell ceremony at the @NasdaqExchange MarketSite in New York City. $IMRX
🧬 Helping cancer patients live longer and feel better. 🏥 @Immuneering is a clinical-stage oncology company developing medicines to help outpace cancer. 💜 Thank you for helping to rewrite futures, $IMRX!
In this article, @cure_today provides an overview of key results we shared from the ongoing Phase 2a clinical trial assessing our potential therapy atebimetinib in first-line #PancreaticCancer patients, including positive overall survival data. Read here: curetoday.com/view/atebimeti…
Thank you @PharmaScrip for covering the positive overall survival data we reported from the ongoing Phase 2a trial of our potential therapy atebimetinib in first-line #PancreaticCancer patients. Read more: insights.citeline.com/scrip/r-and-d/…
In an interview with @PharmExec, CEO Ben Zeskind, PhD, discusses our work to pioneer a new potential approach to #cancer treatment that prioritizes durability and tolerability. Read more about our focus on addressing challenges related to drug resistance: pharmexec.com/view/changing-…
In this article, @CancerNetwork highlights positive results from the ongoing Phase 2a trial evaluating our lead product candidate atebimetinib in first-line #PancreaticCancer—one of the most difficult-to-treat forms of cancer: cancernetwork.com/view/atebimeti…
The entire Immuneering team came together for our Spring Summit to reconnect, collaborate, and recharge. We are proud of the culture we’re building and our shared commitment to translating deep science into impact for people living with #cancer and their families.
In an ongoing Phase 2a trial, we are evaluating a potential new approach to MEK inhibition to help overcome issues associated with standard MEK inhibitors. Read more about our recently reported overall survival data in #PancreaticCancer: firstwordpharma.com/story/5973394 @FirstWordPharma
Check out this @ThePharmaLetter article breaking down the latest positive survival data reported from our ongoing Phase 2a trial in #PancreaticCancer, exploring how our approach may address tolerability challenges associated with standard MEK inhibitors: thepharmaletter.com/biotechnology/…
Positive overall survival data from our ongoing Phase 2a trial in #PancreaticCancer represent a key development in potentially addressing challenges associated with standard MEK inhibitors, including issues with tolerability. Read more: fiercebiotech.com/biotech/immune… @FierceBiotech
We believe innovation in MEK inhibition is critical to help outpace #cancer so patients can outlive their disease. Read about our investigational approach that aims to address key issues associated with standard MEK inhibitors: pharmavoice.com/news/mek-cance… @kellyb720 @PharmaVoice
In this @Forbes article, $IMRX CEO Ben Zeskind, PhD, discusses our work to reimagine #cancer treatment through a new approach to MEK inhibition, and shares insights on the latest data from our ongoing Phase 2a study in #PancreaticCancer: forbes.com/sites/innovati… @TheAlexKnapp
We are pleased to share that the USPTO has granted a composition of matter patent for our lead product candidate, marking the first U.S. patent granted on a deep cyclic inhibitor. For details, see our press release: ir.immuneering.com/news-releases/…
We are proud to sponsor this panel discussion on July 10 hosted by @PanCAN President and CEO @JulieFleshman to share information about the impactful resources offered through the PanCAN Patient Services program to support the #pancreaticcancer community: pancan.org/facing-pancrea…
PanCAN Patient Services is a lifeline for people facing #pancreaticcancer. Every call or email we receive, our Case Managers are there, ready to provide support, offer resources and more — often becoming a trusted partner for patients and families as they navigate this…
Positive overall survival data from our ongoing Phase 2a study reinforce the potential of our investigational therapy atebimetinib to serve as an important component in the management of #PancreaticCancer. Check out the article from @BioWorld below to learn more.
Cheering @Immuneering, Street hopes high in #pancreaticcancer bioworld.com/articles/721338 #biopharma #clinical
Guided by our goal to help people with #cancer live longer and feel better, we are deeply honored to support @PanCAN as a Scientific & Medical Affairs Industry Champion. Learn more about PanCAN’s key research initiatives here: pancan.org/research/
#ICYMI: Last week $IMRX announced a critical update from our Phase 2a clinical trial with atebimetinib (IMM-1-104) highlighting positive overall survival data in first-line #PancreaticCancer patients. Watch the webcast replay of our conference call: ir.immuneering.com/events/event-d…
The positive overall survival data from our Phase 2a clinical trial with atebimetinib (IMM-1-104) in #PancreaticCancer represent a key development in our efforts to outpace #cancer to help patients outlive their disease. Learn more: endpoints.news/immuneering-re… @endpts @ByLizC
We are focused on advancing innovation in MEK inhibition with the potential to help address key challenges associated with current standard of care treatments for MAPK-driven tumors, including issues related to tolerability. Learn more: immuneering.com/pipeline/
